RecruitingPhase 4

Adenosine vs Diltiazem for Treatment of SVT in the ED

United States20 participantsStarted 2025-08-01

Plain-language summary

This is a small, pilot study with a primary goal of assessing patient perceptions of two medication treatments for supraventricular tachycardia in adult patients treated in the Emergency Department.

Who can participate

Age range18 Years – 100 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Adult patients (18 years and older)
✓. Diagnosis of acute, stable SVT in the emergency department

Exclusion criteria

✕. Receipt of IV AV-nodal blocking agents prior to study enrollment (includes adenosine, non-dihydropyridine calcium channel blockers, beta-antagonists in pre-hospital and/or hospital setting).
✕. Reported or confirmed personal history of Wolff-Parkinson-White (WPW) syndrome
✕. History of heart failure with reduce ejection fraction (HFrEF) (LVEF\</= 40%)
✕. Severe bronchoconstrictive lung disease
✕. Prior hypersensitivity to study medication
✕. Previously enrolled in pilot study
✕. Pregnant
✕. Incarcerated

What they're measuring

Feasibility outcome

Timeframe: From enrollment to the end of ED encounter (up to 24 hours).

Feasibility outcome

Timeframe: From enrollment to the end of ED encounter (up to 24 hours).

Feasibility outcome

Timeframe: From enrollment to the end of ED encounter (up to 24 hours).

Trial details

NCT IDNCT06993038

SponsorAnne E. Zepeski

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-07

Contact for this trial

Anne Zepeski, PharmD

(319) 356-2577 anne-zepeski@uiowa.edu

View on ClinicalTrials.gov More Supraventricular Tachycardia (SVT) trials